Activating point mutations of MET and MET amplification have been reported in several cancer types, including gastric cancer [59], breast cancer [60], hepatocellular carcinoma [61, 62], and non-small cell lung cancer [63, 64]. This evidence concerns the gene MET and hepatocellular carcinoma.